Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity.

Autor: Di Staso R; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy., Casadei B; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Gentilini M; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Guadagnuolo S; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Pellegrini C; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Broccoli A; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Gori D; Dipartimento Di Scienze Biomediche E Neuromotorie (DIBINEM), Università Di Bologna, Bologna, Italy., Masetti R; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy.; Pediatric Oncology and Hematology, IRCCS Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy., Stefoni V; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Bonifazi F; IRCCS Azienda-ospedaliero Universitaria Di Bologna, Bologna, Italy., Zinzani PL; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia 'Seràgnoli', Bologna, Italy., Argnani L; Dipartimento Di Scienze Mediche E Chirurgiche (DIMEC), Università Di Bologna, Via Massarenti, 9-40138, Bologna, Italy. lisa.argnani@unibo.it.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 Jul; Vol. 103 (7), pp. 2499-2509. Date of Electronic Publication: 2024 May 02.
DOI: 10.1007/s00277-024-05766-0
Abstrakt: Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive large B-cell lymphoma who underwent leukapheresis between August 2019 and August 2022. All costs and medical resource consumption accountability were calculated on an intention-to-treat (ITT) basis, starting from leukapheresis to the time when the patient (infused or not) exited the CAR T-cell pathway for any reason. Eighty patients were addressed to leukapheresis and 59 were finally infused. After excluding CAR-T product cost, the main driver of higher costs were hospitalizations followed by the examinations/procedures and other drugs, respectively 43.9%, 26.3% and 25.4% of the total. Regarding costs of drugs and medications other than CAR T products, the most expensive items are those referred to AEs, both infective and extra-infective within 30 days from infusion, that account for 63% of the total. Density plot of cost analyses did not show any statistically significant difference with respect to the years of leukapheresis or infusion. To achieve finally 59/80 infused patients the per capita patients without CAR-T products results 74,000 euros. This analysis covers a growing concern on health systems, the burden of expenses related to CAR T-cell therapy, which appears to provide significant clinical benefit despite its high cost, thus making economic evaluations highly relevant. The relevance of this study should be also viewed in light of continuously evolving indications for this therapy.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: